Drug Trial Radar · NCT06614751
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
Last checked: Nov 19, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
Nov 1, 2024
Primary completion
Nov 1, 2026
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- Danatlas Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function alterations and/or other defects in the DNA damage repair (DDR) pathway.
Conditions
- Solid Cancers
- BRCA Mutation
- HRD Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Endometrial Cancer
- Gastric Cancer
- Advanced Cancer
- Metastatic Solid Tumors
Interventions
DAT-2645 tabletDrug
The patient will be randomized into 2 groups and take DAT-2645 tablet daily. dosage is optimal dose-1 or optimal dose-2, 21day/ Cycle. The subject of this part is to optimize dosage and definite RP2D.
DAT-2645 tabletDrug
The study set 6 dose level cohorts in dose escalation part.On C0D1, patient take DAT-2645 one time (Single use), The dosage is same as his enrolled cohort dose level. if no DLT, 7 days later(C1D1), patients will continue taking DAT-2645 tablet daily, dasage is same as before, 21days/cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1, Dose esclalation study:To characterize the safety and tolerability of DAT-2645 monotherapy by evaluating the number of participants with dose limiting toxicities, adverse events, and laboratory abnormalities as graded by NCI CTCAE version 5.0Time frame: 6 months
- Part 2, Dose expansion study: To evaluate preliminary preliminary anti-tumor activity of DAT-2645 tablet monotherapy in participants by measuring tumor Overall Response Rate using RECIST criteria v1.1Time frame: Approximately 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital and Institute
Beijing, Beijing Municipality, China
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijjing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.